Cellares is creating the future of cell therapy manufacturing and accelerating access to life-saving cell therapies. The company is developing a one-of-a-kind solution to overcome the limitations associated with manufacturing cell therapies to make them more affordable and widely available to patients in need. With Cellares' proprietary platform—The Cell Shuttle—biopharma companies, academic research centers and CDMOs will no longer have to compromise by either choosing a manufacturing platform that is semi-automated but lacks workflow flexibility, or one that provides customization but not the end-to-end automation needed to manufacture at scale. PACT Pharma and the Fred Hutchinson Cancer Research Center have joined Cellares' Early Access Partnership Program to participate in user studies, inform system specifications, and provide feedback on the Cell Shuttle to help ensure product-market fit. The company is headquartered in South San Francisco, Calif. For more information visit www.cellares.com.